April 15th 2021
Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.
April 12th 2021
Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.
April 8th 2021
Dr. Weiss discusses the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.
April 5th 2021
In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.
April 1st 2021
The Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.
March 29th 2021
Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.
March 25th 2021
Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.
March 22nd 2021
Patrick I. Borgen, MD, discusses male breast cancer in further detail, how he approaches treatment in his male patients with the disease, and what can be done to remove the stigma that men often feel with a breast cancer diagnosis.
March 18th 2021
In our exclusive interview, Dr. Monk and Dr. Herzog discuss the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.
March 15th 2021
Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.
March 11th 2021
Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.
March 8th 2021
Dr. Shitara discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-positive gastric and GEJ adenocarcinoma and key efficacy and safety data that have been reported with the agent.
March 4th 2021
John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.
March 1st 2021
In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.
February 25th 2021
Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.
February 22nd 2021
In our exclusive interview, Dr. Nichols discusses von Hippel-Lindau disease in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.
February 18th 2021
In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.
February 11th 2021
Dr. Klempner provides insight into unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.
February 8th 2021
Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.